{
    "nct_id": "NCT05562830",
    "official_title": "A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A",
    "inclusion_criteria": "The main inclusion and exclusion criteria include but are not limited to the following:\n\n* Histologically or cytologically confirmed diagnosis of locally advanced/unresectable or mUC of the renal pelvis, ureter (upper urinary tract), bladder, or urethra.\n* PD-1/L1 refractory locally advanced or mUC as evidenced by:\n\nEITHER disease progression while on treatment or after treatment with an anti-PD-1/L1 monoclonal antibody (mAb) for locally advanced/unresectable or mUC administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies OR disease recurrence while on treatment or after treatment with an anti-PD-1/L1 mAb for muscle-invasive urothelial carcinoma (MIUC) administered as monotherapy.\n\n* Participants must provide an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion demonstrating UC, not previously irradiated, and adequate for biomarker evaluation.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known additional nonurothelial malignancy that is progressing or has required active treatment within 3 years prior to study randomization/allocation.\n* Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization/allocation.\n* Active infection requiring systemic therapy.\n* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.\n* Known history of human immunodeficiency virus (HIV).\n* Known history of hepatitis B or known hepatitis C virus infection.",
    "miscellaneous_criteria": ""
}